FDA approves Alzheimer’s blood test that rivals spinal taps, brain scans

The FDA has cleared C2N Diagnostics’ PrecivityAD2 blood test for marketing, giving physicians a less invasive way to identify amyloid plaques associated with Alzheimer’s disease in certain patients. C2N Diagnostics developed and validated the test using underlying technology invented at Washington University School of Medicine in St. Louis, according to an Aug. 21 news release. […] The post FDA approves Alzheimer’s blood test that rivals spinal taps, brain scans appeared...